Can a targeted shoulder nerve block cut Post-Surgery pain and morphine use?
NCT ID NCT07808008
First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time
Summary
This trial tests whether a specific nerve block, called the infraspinatus-teres minor (ITM) block, can control pain after shoulder arthroscopy. The block involves injecting anesthetic between two muscles in the back of the shoulder to numb the nerves. Researchers will measure pain scores and morphine use in the first 24 hours after surgery to see if the block provides acceptable pain relief.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Infraspinatus-teres minor (ITM) interfascial plane block, an injection of local anesthetic between two shoulder muscles to numb nerves
- What this could lead to
- If effective, this nerve block could offer better pain control after shoulder surgery, reducing the need for morphine and its side effects.
- What could go wrong
- This is a small early-stage trial, so results may not apply broadly. The block might not provide adequate pain relief for all patients, and there are risks like nerve damage or infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 29 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * The study population inclusion criteria will be: * Patients of any sex * Class ASAI-III * Patients 18 years of age or older * Scheduled for elective shoulder arthroscopy * Able to give written informed consent autonomously * Sex and gender dimensions are irrelevant for this study as enrolled patients are benefitting from shoulder surgery without reference to gender and our standard care as well as our research disposition is indiscriminately applied to all genders. Exclusion Criteria: * The subject exclusion criteria will be: * Allergy to any of: ropivacaine, paracetamol, celecoxib, morphine, ondansetron or dexamethasone * Refusal or inability to give consent * Bleeding diathesis (according to HEMSTOP score) * Neurological deficit of the operative side * Existing preoperative chronic opioid use (greater than or equal to 3 months of use) * Renal insufficiency (GFR\<30ml/min according to the Cockroft-Gault formula) * Known or suspected non-compliance * Illicit drug use * Excessive alcohol use (\<8 drinks per week for women, \>15 drinks per week for men) * Inability to follow the procedures of the study, e.g due to language problems, psychiatric disorder, dementia, etc * Participation in another study with an investigational medicinal product within 30 days preceding the study and during the study * Hepatic insufficiency (CHILD-Pugh score B or C) * Enrolment of the investigator, his/her family members, employees and other dependent persons
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Postoperative pain after shoulder arthroscopy are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Centre Hospitalier Universitaire Vaudois-CHUV
Lausanne, Canton of Vaud, 1011, Switzerland